Ahmad Mourad
Overview
Explore the profile of Ahmad Mourad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
411
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mourad A, Grandits G, Siegel L, Engen N, Barkauskas C, Eriobu N, et al.
Clin Microbiol Infect
. 2025 Feb;
PMID: 39922466
Objectives: Passive immunotherapy, including monoclonal antibodies and neutralizing proteins, was used for the treatment of patients with COVID-19 during the pandemic. Accelerating COVID-19 Therapeutic Interventions and Vaccines-Therapeutics for Inpatients with...
2.
OHalloran J, Beitler J, Chung L, Jain M, Khan A, Merck L, et al.
J Clin Transl Sci
. 2024 Nov;
8(1):e154.
PMID: 39540117
Background: The COVID-19 pandemic amplified known challenges associated with the conduct of inpatient clinical trials, while also introducing new ones that needed to be addressed. Methods: Stakeholders based in the...
3.
4.
Rothman R, Stewart T, Mourad A, Boulware D, McCarthy M, Thicklin F, et al.
JAMA Netw Open
. 2024 Oct;
7(10):e2439332.
PMID: 39422912
Importance: The effect of montelukast in reducing symptom duration among outpatients with mild to moderate COVID-19 is uncertain. Objective: To assess the effectiveness of montelukast compared with placebo in treating...
5.
Mourad A, Nwafo N, Skalla L, Holland T, Jenkins T
Clin Infect Dis
. 2024 Sep;
80(1):29-36.
PMID: 39290168
Background: We conducted a systematic review of randomized, controlled trials (RCTs) to generate more precise estimates of the efficacy and safety of oral versus intravenous antibiotic therapy for Staphylococcus aureus...
6.
Smith A, Yarrington M, Baker A, Cox G, Dicks K, Engemann J, et al.
Clin Infect Dis
. 2024 Jun;
79(4):864-870.
PMID: 38867715
Background: Infectious diseases (ID) physicians are increasingly faced with the challenge of caring for patients with terminal illnesses or incurable infections. Methods: This was a retrospective cohort of all patients...
7.
Mourad A, Niehaus E, Fowler Jr V, Holland T
Clin Microbiol Infect
. 2024 Jun;
30(9):1199-1201.
PMID: 38851425
No abstract available.
8.
Rothman R, Stewart T, Mourad A, Boulware D, McCarthy M, Thicklin F, et al.
medRxiv
. 2024 May;
PMID: 38798524
Importance: The effect of montelukast in reducing symptom duration among outpatients with mild to moderate coronavirus disease 2019 (COVID-19) is uncertain. Objective: To assess the effectiveness of montelukast compared with...
9.
Mourad A, Smith A, Troy J, Holland T, Wrenn R, Turner N
J Antimicrob Chemother
. 2024 May;
79(6):1456-1461.
PMID: 38708907
Background: A small proportion of Escherichia coli and Klebsiella pneumoniae demonstrate in vitro non-susceptibility to piperacillin/tazobactam but retain susceptibility to ceftriaxone. Uncertainty remains regarding how best to treat these isolates....
10.
Hillenbrand M, Mourad A, Holland T, Turner N
Clin Microbiol Infect
. 2024 Feb;
30(6):703-706.
PMID: 38341142
No abstract available.